<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01548092</url>
  </required_header>
  <id_info>
    <org_study_id>EC10-343</org_study_id>
    <secondary_id>2010-024330-35</secondary_id>
    <nct_id>NCT01548092</nct_id>
  </id_info>
  <brief_title>Stromal Vascular Fraction (SVF) for Treatment of Recto-vaginal Fistula</brief_title>
  <acronym>HULPCIR</acronym>
  <official_title>A Phase II Clinical Trial to Study the Feasibility and Safety of Stromal Vascular Derived From Adipose Tissue for the Treatment of Recto-vaginal Fistula</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigación Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Investigación Hospital Universitario La Paz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine safety of Stromal Vascular Fraction (SVF) for the
      treatment of recto-vaginal fistula.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SF-12 Test
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of treatment of treated recto-vaginal fistulae. Percentage of treated enterocutaneous fistulae and percentage of subjects with closed fistulae</measure>
    <time_frame>16 weeks</time_frame>
    <description>Safety by control the adverse effects associated with treatment Fistula close by 3D ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment using the SF-12 Questionnaire</measure>
    <time_frame>1, 4, 16, 24 weeks</time_frame>
    <description>Test SF-12 of quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>1, 4, 12, 24 weeks</time_frame>
    <description>Control by investigation team of CRD (data collections)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Recto-vaginal Fistula</condition>
  <arm_group>
    <arm_group_label>Autologous SVF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intralesional application</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adipose-derived stem cells without expanded</intervention_name>
    <description>Administration will be intralesional injection of cells suspension. They will be placed into fistula walls</description>
    <arm_group_label>Autologous SVF</arm_group_label>
    <other_name>Adipose-Derived Mesenchymal Stem Cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Recto-vaginal fistula

          -  Men and women over 18 years old. Good general state of health according to the
             findings of the clinical history and the physical examination

          -  Crohn's disease diagnosed at least 3 months before accepting the clinical criteria

        Exclusion Criteria:

          -  Presence of severe proctitis or dominant active luminal disease requiring immediately
             therapy

          -  Patients with an abscess unless a complete toilet of the area with drainage of the
             collections and the absence of abscess and other collections is confirmed prior to
             treatment start

          -  Patients with a history of abuse of alcohol or other addictive substances in the 6
             months prior to inclusion

          -  Patients with malignant tumor, except for basal cell or cutaneous squamous cell
             carcinoma, or patients with a prior history of malignant tumors, unless the neoplastic
             disease has been in remission for the previous 5 years

          -  Patients with cardiopulmonary disease which, in opinion of the investigator, in
             unstable or sufficiently serious to exclude the patient from the study.

          -  Patients with any type of medical or psychiatric disease which, in the opinion of the
             investigator, could be grounds for exclusion from study

          -  Patients with congenital or acquired immunodeficiencies. HIV, hepatitis B virus (HBV),
             hepatitis C virus (HCV) or treponema infection, whether active or latent

          -  Patients who have suffering major surgery or severe trauma in the prior 6 months

          -  Pregnant or breastfeeding women

          -  Patients currently receiving, or having received within 1 month prior to enrollment
             into this clinical trial, any investigational drug.

          -  Crohns Disease Activity Index (CDAI) Index above 200
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariano García Arranz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cell Therapy laboratory and general Surgery Department, Hospital Universitario La Paz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mariano Garcia Arranz</last_name>
    <phone>+34912071022</phone>
    <email>mgarciaa.hulp@salud.madrid.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Dolores Herreos</last_name>
    <phone>+34912071022</phone>
    <email>loles.herreros@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28039</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariano García Arranz</last_name>
      <phone>+34912071022</phone>
      <email>mgarciaa.hulp@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Maria Dolores Herreros</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Damián García Olmo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tihomir Hirstov</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Héctor Guadalajara</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>García-Olmo D, García-Arranz M, García LG, Cuellar ES, Blanco IF, Prianes LA, Montes JA, Pinto FL, Marcos DH, García-Sancho L. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn's disease: a new cell-based therapy. Int J Colorectal Dis. 2003 Sep;18(5):451-4. Epub 2003 May 20.</citation>
    <PMID>12756590</PMID>
  </reference>
  <reference>
    <citation>García-Olmo D, García-Arranz M, Herreros D, Pascual I, Peiro C, Rodríguez-Montes JA. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005 Jul;48(7):1416-23.</citation>
    <PMID>15933795</PMID>
  </reference>
  <reference>
    <citation>Herreros Marcos D, Garcia-Arranz M,Pascual Miguelañez I, Garcia-Olmo D. THE ROLE OF STEM CELLS IN SUPPURATIVE ENVIROMENTS. Experimental Dermatology 2006, 15 (6): 482</citation>
  </reference>
  <reference>
    <citation>Garcia-Olmo D, Herreros D, Pascual M, Pascual I, De-La-Quintana P, Trebol J, Garcia-Arranz M. Treatment of enterocutaneous fistula in Crohn's Disease with adipose-derived stem cells: a comparison of protocols with and without cell expansion. Int J Colorectal Dis. 2009 Jan;24(1):27-30. doi: 10.1007/s00384-008-0559-0. Epub 2008 Aug 12.</citation>
    <PMID>18696086</PMID>
  </reference>
  <reference>
    <citation>Alvarez PD, García-Arranz M, Georgiev-Hristov T, García-Olmo D. A new bronchoscopic treatment of tracheomediastinal fistula using autologous adipose-derived stem cells. Thorax. 2008 Apr;63(4):374-6. doi: 10.1136/thx.2007.083857.</citation>
    <PMID>18364447</PMID>
  </reference>
  <reference>
    <citation>Vilalta M, Dégano IR, Bagó J, Gould D, Santos M, García-Arranz M, Ayats R, Fuster C, Chernajovsky Y, García-Olmo D, Rubio N, Blanco J. Biodistribution, long-term survival, and safety of human adipose tissue-derived mesenchymal stem cells transplanted in nude mice by high sensitivity non-invasive bioluminescence imaging. Stem Cells Dev. 2008 Oct;17(5):993-1003. doi: 10.1089/scd.2007.0201.</citation>
    <PMID>18537463</PMID>
  </reference>
  <reference>
    <citation>Garcia-Olmo D, Herreros D, Pascual I, Pascual JA, Del-Valle E, Zorrilla J, De-La-Quintana P, Garcia-Arranz M, Pascual M. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum. 2009 Jan;52(1):79-86. doi: 10.1007/DCR.0b013e3181973487.</citation>
    <PMID>19273960</PMID>
  </reference>
  <reference>
    <citation>Pascual I, de Miguel GF, Gómez-Pinedo UA, de Miguel F, Arranz MG, García-Olmo D. Adipose-derived mesenchymal stem cells in biosutures do not improve healing of experimental colonic anastomoses. Br J Surg. 2008 Sep;95(9):1180-4. doi: 10.1002/bjs.6242.</citation>
    <PMID>18690635</PMID>
  </reference>
  <reference>
    <citation>García Olmo D, Trébol J, Herreros D, Garcia-Arranz M, Gonzalez M. TREATMENT OF FISTULAS USING ADIPOSE-DERIVED STEM CELLS. En: García Olmo D, García-Verdugo JM, Alemany J, Gonzalez M, Gutierrez-Fuentes JA. CELL THERAPHY . Ed. Mac Graw Hill. Madrid 2007)</citation>
  </reference>
  <reference>
    <citation>Garcia-Olmo D, Garcia-Arranz M, Herreros D. Expanded adipose-derived stem cells for the treatment of complex perianal fistula including Crohn's disease. Expert Opin Biol Ther. 2008 Sep;8(9):1417-23. doi: 10.1517/14712598.8.9.1417 . Review.</citation>
    <PMID>18694359</PMID>
  </reference>
  <reference>
    <citation>Garcia-Olmo, D; Guadalajara, H; Trebol, J, García-Arranz M. Expanded Adipose-Derived Stem Cells for the Treatment of Complex Perianal Fistula. HUMAN GENE THERAPY 2009. 20 (9):1028-1028</citation>
  </reference>
  <reference>
    <citation>Trebol, J; Garcia-Arranz, M; Georgiev-Hristov, T, et al. Cell Therapy for Enterocutaneous Fistula Associated with Crohn's Disease: A Clinical and Biological Comparison of Protocols With and Without Cell Expansion. HUMAN GENE THERAPY 2009. 20 (9): 1045-1045</citation>
  </reference>
  <reference>
    <citation>Garcia-Gomez, I; Olmedillas, S; Garcia-Arranz, M, et al. Adipose-Derived Stem Cells Reduce Abdominal Adhesion Formation in a Rat Experimental Model. HUMAN GENE THERAPY 2009. 20 (9): 1047-1047</citation>
  </reference>
  <reference>
    <citation>Georgiev-Hristov, T; Garcia-Olmo, D; Alvarez, PDA, et al. Use of Surgical Sutures Enriched with Adipose-Derived Stem Cells for Tracheal Anastomosis in Rats. HUMAN GENE THERAPY 2009. 20 (9): 1074-1075</citation>
  </reference>
  <reference>
    <citation>Vicente, A; Vazquez, MN; Entrena, A, Gqarcía-Arranz M,et al. BMP-4 Regulates the Expansion and Survival of Human Adipose Mesenchymal Cells. HUMAN GENE THERAPY .2009. 20 (9):1080-1081</citation>
  </reference>
  <reference>
    <citation>García-Olmo DC, Domínguez C, García-Arranz M, Anker P, Stroun M, García-Verdugo JM, García-Olmo D. Cell-free nucleic acids circulating in the plasma of colorectal cancer patients induce the oncogenic transformation of susceptible cultured cells. Cancer Res. 2010 Jan 15;70(2):560-7. doi: 10.1158/0008-5472.CAN-09-3513. Epub 2010 Jan 12.</citation>
    <PMID>20068178</PMID>
  </reference>
  <reference>
    <citation>García-Arranz M, Gómez-Pinedo U, Hardisson D, Herreros D, Guadalajara H, García-Gómez I, García-Verdugo JM, García-Olmo D. Histopathological analysis of human specimens removed from the injection area of expanded adipose-derived stem cells. Histopathology. 2010 Jun;56(7):979-82. doi: 10.1111/j.1365-2559.2010.03573.x.</citation>
    <PMID>20636801</PMID>
  </reference>
  <reference>
    <citation>Tihomir Georgiev-Hristov, M.D.; Ignacio García-Gómez, Ph.D.; Prudencio Díaz-Agero, M.D.; Luz Vega-Clemente; Jacobo Trébol, M.D.; Damián García-Olmo, M.D., Ph.D.; Mariano García-Arranz, Ph.D. &quot;SUTURES ENRICHED WITH ADIPOSE-DERIVED STEM CELLS FOR ENHANCED HEALING OF TRACHEAL ANASTOMOSIS IN RATS&quot; Histology and Histopathology. 2010 (UNDER REVISION)</citation>
  </reference>
  <reference>
    <citation>García-Olmo D, Herreros D, De-La-Quintana P, Guadalajara H, Trébol J, Georgiev-Hristov T, García-Arranz M.</citation>
  </reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2012</study_first_submitted>
  <study_first_submitted_qc>March 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2012</study_first_posted>
  <last_update_submitted>March 5, 2012</last_update_submitted>
  <last_update_submitted_qc>March 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recto-vaginal fistula</keyword>
  <keyword>Adipose Derived Stem Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fistula</mesh_term>
    <mesh_term>Vaginal Fistula</mesh_term>
    <mesh_term>Rectovaginal Fistula</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

